Sanuwave Health (NASDAQ:SNWV) and Agilent Technologies (NYSE:A) Financial Survey

Sanuwave Health (NASDAQ:SNWV) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Risk & Volatility

Sanuwave Health has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Insider and Institutional Ownership

42.5% of Sanuwave Health shares are owned by institutional investors. 14.4% of Sanuwave Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Sanuwave Health and Agilent Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanuwave Health	$44.05 million	3.22	$11.81 million	$0.33	50.05
Agilent Technologies	$6.95 billion	5.48	$1.30 billion	$4.53	29.74

Agilent Technologies has higher revenue and earnings than Sanuwave Health. Agilent Technologies is trading at a lower price-to-earnings ratio than Sanuwave Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sanuwave Health and Agilent Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanuwave Health	35.96%	-450.56%	44.87%
Agilent Technologies	19.55%	24.74%	13.11%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sanuwave Health and Agilent Technologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanuwave Health	1	1	1	1	2.50
Agilent Technologies	0	1	13	2	3.06

Sanuwave Health currently has a consensus price target of $51.00, suggesting a potential upside of 208.79%. Agilent Technologies has a consensus price target of $160.93, suggesting a potential upside of 19.44%. Given Sanuwave Health’s higher possible upside, equities research analysts plainly believe Sanuwave Health is more favorable than Agilent Technologies.

Summary

Agilent Technologies beats Sanuwave Health on 8 of the 15 factors compared between the two stocks.

About Sanuwave Health

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company’s lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

About Agilent Technologies

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer’s representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.